The latest emerging roles of non-promoter CpG islands of cancer-related genes and the translational impact of KEAP1/NRF2 point mutations in predicting resistance to treatment further beg the question of the translational utility of KEAP1 methylation in the clinical context. This evidence concerns the gene NFE2L2 and cancer.